Published in Wien Med Wochenschr on January 01, 2009
[Update on diabetic macroangiopathy]. Pathologe (2012) 0.76
[Diabetes mellitus]. Wien Med Wochenschr (2009) 0.75
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med (2000) 29.25
Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med (1998) 25.66
Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care (1993) 17.66
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med (1991) 16.19
Cellular mechanisms of insulin resistance. J Clin Invest (2000) 12.61
Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature (2000) 12.33
Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med (1987) 8.77
Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation (1999) 8.04
Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J (2005) 7.75
Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A (2000) 5.65
Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol (2000) 5.59
Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes (1974) 5.55
Diabetes and cardiovascular risk factors: the Framingham study. Circulation (1979) 5.32
New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol (1972) 4.86
Prevention of fat-induced insulin resistance by salicylate. J Clin Invest (2001) 4.74
Diabetes, hypertension, and cardiovascular disease: an update. Hypertension (2001) 4.62
Diabetic cardiovascular autonomic neuropathy. Circulation (2007) 4.58
How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ (2005) 4.31
Advanced protein glycosylation in diabetes and aging. Annu Rev Med (1995) 4.13
Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care (2001) 4.09
Natriuretic peptides. J Am Coll Cardiol (2007) 3.91
Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet (2008) 3.71
Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev (2004) 3.69
Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation (2003) 3.30
Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res (2006) 3.27
Myocardial cell death in human diabetes. Circ Res (2000) 3.12
Glycemic control and heart failure among adult patients with diabetes. Circulation (2001) 2.99
Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest (2003) 2.95
The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care (2004) 2.79
Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes (2002) 2.44
H(2)O(2) regulates cardiac myocyte phenotype via concentration-dependent activation of distinct kinase pathways. J Mol Cell Cardiol (2003) 2.31
Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy. J Am Coll Cardiol (2006) 2.21
Protection of cardiac mitochondria by overexpression of MnSOD reduces diabetic cardiomyopathy. Diabetes (2006) 2.12
Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation (1996) 2.10
Cardiac mitochondrial damage and biogenesis in a chronic model of type 1 diabetes. Am J Physiol Endocrinol Metab (2004) 2.03
Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation (2003) 2.01
Report of the National Heart, Lung, and Blood Institute Special Emphasis Panel on Heart Failure Research. Circulation (1997) 2.00
Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. Eur Heart J (2004) 1.98
Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol (2006) 1.97
Left ventricular systolic and diastolic function in normotensive type 1 diabetic patients with or without autonomic neuropathy: a radionuclide ventriculography study. Diabetes Care (2003) 1.79
Insulin resistance and cardiac mass: the end of the beginning? Obes Res (2003) 1.61
Left ventricular diastolic dysfunction as an early manifestation of diabetic cardiomyopathy. Cardiology (2002) 1.58
Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol (1996) 1.55
Overexpression of the sarcoplasmic reticulum Ca(2+)-ATPase improves myocardial contractility in diabetic cardiomyopathy. Diabetes (2002) 1.54
Mitochondrial uncoupling: a key contributor to reduced cardiac efficiency in diabetes. Physiology (Bethesda) (2006) 1.53
Mechanisms of [Ca2+]i transient decrease in cardiomyopathy of db/db type 2 diabetic mice. Diabetes (2006) 1.49
Lipotoxic diseases of nonadipose tissues in obesity. Int J Obes Relat Metab Disord (2000) 1.37
Subcellular remodeling and heart dysfunction in chronic diabetes. Cardiovasc Res (1998) 1.29
Diabetes mellitus and heart failure: epidemiology, mechanisms, and pharmacotherapy. Am J Cardiol (2006) 1.27
Diabetic cardiomyopathy. A unique entity or a complication of coronary artery disease? Diabetes Care (1995) 1.26
Decreased sarcoplasmic reticulum activity and contractility in diabetic db/db mouse heart. Diabetes (2004) 1.17
Cardiomyocyte apoptosis induced by short-term diabetes requires mitochondrial GSH depletion. Am J Physiol Heart Circ Physiol (2005) 1.14
Diabetic cardiomyopathy. Diabetes Care (1990) 1.11
Suppression of nitrative damage by metallothionein in diabetic heart contributes to the prevention of cardiomyopathy. Free Radic Biol Med (2006) 1.09
Diabetic heart disease. Heart (2005) 1.06
Cardiovascular oxidative stress is reduced by an ACE inhibitor in a rat model of streptozotocin-induced diabetes. Life Sci (2006) 1.05
Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy. J Am Coll Cardiol (2004) 1.03
Diminished function and expression of the cardiac Na+-Ca2+ exchanger in diabetic rats: implication in Ca2+ overload. J Physiol (2000) 1.00
Hyperglycemia as a cardiovascular risk factor. Am J Med (2003) 1.00
Streptozotocin directly impairs cardiac contractile function in isolated ventricular myocytes via a p38 map kinase-dependent oxidative stress mechanism. Biochem Biophys Res Commun (2004) 0.98
Associations of insulin levels with left ventricular structure and function in American Indians: the strong heart study. Diabetes (2002) 0.98
Decreased high-energy phosphate ratios in the myocardium of men with diabetes mellitus type I. J Cardiovasc Magn Reson (2002) 0.98
Plasma NT-proBNP increases in response to LPS administration in healthy men. J Appl Physiol (1985) (2008) 0.98
Regulation and role of the mitochondrial transcription factor in the diabetic rat heart. Ann N Y Acad Sci (2004) 0.95
Diabetes mellitus and risk of idiopathic dilated cardiomyopathy. The Washington, DC Dilated Cardiomyopathy Study. Ann Epidemiol (1994) 0.94
Diabetic cardiomyopathy. Endocrinol Metab Clin North Am (2006) 0.94
Relationship of insulin sensitivity and left ventricular mass in uncomplicated obesity. Obes Res (2003) 0.94
Production and metabolism of ceramide in normal and ischemic-reperfused myocardium of rats. Basic Res Cardiol (2001) 0.94
Cardiac myofibrillar ATPase activity in diabetic rats. J Mol Cell Cardiol (1981) 0.94
Autonomic innervation of the human cardiac conduction system: changes from infancy to senility--an immunohistochemical and histochemical analysis. Anat Rec (2001) 0.93
Diabetes mellitus and coronary heart disease. Endocrinol Metab Clin North Am (2001) 0.92
Effects of tumor necrosis factor-alpha on insulin action in cultured human muscle cells. Diabetes (2001) 0.92
Turning down insulin signaling. J Clin Invest (2001) 0.91
Mitochondrial dysfunction observed in situ in cardiomyocytes of rats in experimental diabetes. Cardiovasc Res (1992) 0.90
Signal transduction and Ca2+ signaling in intact myocardium. J Pharmacol Sci (2006) 0.89
Radionuclide assessment of left ventricular diastolic filling in diabetes mellitus with and without cardiac autonomic neuropathy. J Am Coll Cardiol (1986) 0.89
Decreased cardiac sarcoplasmic reticulum Ca2+ -ATPase activity contributes to cardiac dysfunction in streptozotocin-induced diabetic rats. J Physiol Biochem (2006) 0.88
Brain Natriuretic Peptide (BNP) regulates the production of inflammatory mediators in human THP-1 macrophages. Regul Pept (2008) 0.87
Alterations in ion channel physiology in diabetic cardiomyopathy. Endocrinol Metab Clin North Am (2006) 0.87
Heart mitochondrial function in chronic experimental diabetes in rats. Can J Cardiol (1985) 0.86
NT-proBNP has a high negative predictive value to rule-out short-term cardiovascular events in patients with diabetes mellitus. Eur Heart J (2008) 0.86
Cardiac sarcoplasmic reticulum function in insulin- or carnitine-treated diabetic rats. Am J Physiol (1983) 0.85
Hyperglycemia does not alter state 3 respiration in cardiac mitochondria from type-I diabetic rats. Mol Cell Biochem (2004) 0.84
Influence of autonomic neuropathy upon left ventricular dysfunction in insulin-dependent diabetic patients. Clin Cardiol (2000) 0.83
Diabetes and atherogenesis. Heart (2004) 0.82
Mitochondrial creatine phosphokinase deficiency in diabetic rat heart. Biochem Biophys Res Commun (1988) 0.81
Myocardial dysfunction and adrenergic innervation in patients with Type 1 diabetes mellitus. Diabetes Nutr Metab (2000) 0.80
Isoenzyme profiles of creatine kinase, lactate dehydrogenase, and aspartate aminotransferase in the diabetic heart: comparison with hereditary and catecholamine cardiomyopathies. Cardiovasc Res (1990) 0.78
Diabetes and heart disease an evidence-driven guide to risk factors management in diabetes. Cardiol Rev (2003) 0.77
The ACE-inhibitor captopril improves myocardial perfusion in spontaneously diabetic (BB) rats. Diabetologia (1995) 0.77
Effects of diabetes and hypertension on myocardial Na+-Ca2+ exchange. Can J Physiol Pharmacol (2000) 0.76
Autonomic nervous function and its relationship to cardiac performance in middle-aged diabetic patients without clinically evident cardiovascular disease. J Intern Med (1992) 0.76
Interactions of glucose metabolism and chronic heart failure. Exp Clin Endocrinol Diabetes (2008) 0.76
[Cytokines--causes, players or bystanders in heart failure]. Herz (2002) 0.75
B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation (2002) 4.30
PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial. J Am Coll Cardiol (2013) 2.83
Cardiac magnetic resonance postcontrast T1 time is associated with outcome in patients with heart failure and preserved ejection fraction. Circ Cardiovasc Imaging (2013) 2.47
Short-term effects of levosimendan and prostaglandin E1 on hemodynamic parameters and B-type natriuretic peptide levels in patients with decompensated chronic heart failure. Eur J Heart Fail (2005) 2.17
N-terminal pro-B-type natriuretic peptide is an independent predictor of outcome in an unselected cohort of critically ill patients. Crit Care Med (2007) 1.87
N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study. J Am Coll Cardiol (2010) 1.87
Beneficial effects of chronic low-frequency stimulation of thigh muscles in patients with advanced chronic heart failure. Eur Heart J (2004) 1.87
Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation (2002) 1.64
Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis. Circulation (2004) 1.56
A multi-biomarker risk score improves prediction of long-term mortality in patients with advanced heart failure. Int J Cardiol (2012) 1.51
Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Cancer (2010) 1.50
Impact of tricuspid regurgitation on survival in patients with chronic heart failure: unexpected findings of a long-term observational study. Eur Heart J (2013) 1.46
Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. J Am Coll Cardiol (2008) 1.27
Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem (2008) 1.19
Flow-mediated vasodilation predicts outcome in patients with chronic heart failure: comparison with B-type natriuretic peptide. J Am Coll Cardiol (2005) 1.14
Muscle strength as a predictor of long-term survival in severe congestive heart failure. Eur J Heart Fail (2004) 1.09
The relationship between insulin resistance and the cardiovascular biomarker growth differentiation factor-15 in obese patients. Clin Chem (2010) 1.03
Inorganic phosphate and FGF-23 predict outcome in stable systolic heart failure. Eur J Clin Invest (2011) 1.02
Prognostic value of apoptosis markers in advanced heart failure patients. Eur Heart J (2009) 1.02
Prognostic value of plasma midregional pro-adrenomedullin and C-terminal-pro-endothelin-1 in chronic heart failure outpatients. Eur J Heart Fail (2009) 0.99
Plasminogen activator inhibitor 1 expression is regulated by the inflammatory mediators interleukin-1alpha, tumor necrosis factor-alpha, transforming growth factor-beta and oncostatin M in human cardiac myocytes. J Mol Cell Cardiol (2002) 0.98
Plasma NT-proBNP increases in response to LPS administration in healthy men. J Appl Physiol (1985) (2008) 0.98
Prognostic value of emerging neurohormones in chronic heart failure during optimization of heart failure-specific therapy. Clin Chem (2009) 0.95
Cost analysis and cost-effectiveness of NT-proBNP-guided heart failure specialist care in addition to home-based nurse care. Eur J Clin Invest (2010) 0.94
B-type natriuretic peptide modulates ghrelin, hunger, and satiety in healthy men. Diabetes (2012) 0.93
Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death. J Am Coll Cardiol (2009) 0.93
Bacterial endotoxin induces biphasic changes in plasma ghrelin in healthy humans. J Clin Endocrinol Metab (2007) 0.93
Fractalkine is an independent predictor of mortality in patients with advanced heart failure. Thromb Haemost (2012) 0.91
Chronic heart failure leads to an expanded plasma volume and pseudoanaemia, but does not lead to a reduction in the body's red cell volume. Eur Heart J (2008) 0.90
Differences in the predictive value of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in advanced ischemic and non-ischemic heart failure. Atherosclerosis (2010) 0.90
Plasma osteopontin increases after bariatric surgery and correlates with markers of bone turnover but not with insulin resistance. J Clin Endocrinol Metab (2008) 0.89
Endothelial markers may link kidney function to cardiovascular events in type 2 diabetes. Diabetes Care (2009) 0.89
B-type natriuretic peptide and amino terminal proBNP predict one-year mortality in short of breath patients independently of the baseline diagnosis of acute destabilized heart failure. Clin Chim Acta (2006) 0.88
Plasma MR-proADM correlates to BMI and decreases in relation to leptin after gastric bypass surgery. Obesity (Silver Spring) (2009) 0.88
Serum vaspin concentrations in relation to insulin sensitivity following RYGB-induced weight loss. Obes Surg (2009) 0.87
NT-proBNP has a high negative predictive value to rule-out short-term cardiovascular events in patients with diabetes mellitus. Eur Heart J (2008) 0.86
Cholinergic regulation of ghrelin and peptide YY release may be impaired in obesity. Diabetes (2008) 0.86
B-type natriuretic peptide predicts benefit from a home-based nurse care in chronic heart failure. J Card Fail (2008) 0.86
Influence of age and in-patient care on prescription rate and long-term outcome in chronic heart failure: a data-based substudy of the EuroHeart Failure Survey. Eur J Heart Fail (2005) 0.86
Glycoprotein 130 ligand oncostatin-M induces expression of vascular endothelial growth factor in human adult cardiac myocytes. Cardiovasc Res (2003) 0.86
Prostaglandin E1 induces vascular endothelial growth factor-1 in human adult cardiac myocytes but not in human adult cardiac fibroblasts via a cAMP-dependent mechanism. J Mol Cell Cardiol (2004) 0.85
The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure. Eur J Heart Fail (2004) 0.84
Association of endostatin with mortality in patients with chronic heart failure. Eur J Clin Invest (2013) 0.84
[Heart rate and functional impairment are predictors of outcome in heart failure patients in the real world. Data from the Austrian Heart Failure registry]. Wien Klin Wochenschr (2011) 0.83
Prognostic value of pigment epithelium-derived factor in patients with advanced heart failure. Chest (2010) 0.83
[Diabetes education in adult diabetic patients]. Wien Klin Wochenschr (2012) 0.83
Pathogenesis of bone loss in heart transplant candidates and recipients. J Heart Lung Transplant (2003) 0.82
Endocrine function is not impaired in patients with a continuous MicroMed-DeBakey axial flow pump. J Thorac Cardiovasc Surg (2007) 0.82
Interleukin-6 and B-type natriuretic peptide are independent predictors for worsening of heart failure in patients with progressive congestive heart failure. J Heart Lung Transplant (2004) 0.81
Acute effects of hydrocortisone on the metabolic response to a glucose load: increase in the first-phase insulin secretion. Eur J Endocrinol (2010) 0.81
Levosimendan and prostaglandin E1 for uptitration of beta-blockade in patients with refractory, advanced chronic heart failure. Eur J Heart Fail (2006) 0.81
A comparison of NT-proBNP and albuminuria for predicting cardiac events in patients with diabetes mellitus. Eur J Prev Cardiol (2011) 0.81
[Diabetes and cardiovascular complications]. Wien Med Wochenschr (2010) 0.81
Hepatocyte growth factor is a strong predictor of mortality in patients with advanced heart failure. Heart (2011) 0.81
Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure. Am J Cardiol (2004) 0.80
Clinical and experimental evidence of prostaglandin E1-induced angiogenesis in the myocardium of patients with ischemic heart disease. Cardiovasc Res (2002) 0.80
Sex-specific differences in long-term glycemic control and cardiometabolic parameters in patients with type 1 diabetes treated at a tertiary care centre: gender aspects in type 1 diabetes. Wien Klin Wochenschr (2012) 0.80
Benefit of specialized clinics for the treatment of patients with heart failure. Eur J Intern Med (2011) 0.80
Neurohumoral and hemodynamic effects of the selective endothelin antagonist darusentan in advanced chronic heart failure. J Heart Lung Transplant (2004) 0.80
Prognostic power of neurohumoral parameters in chronic heart failure depends on clinical stage and observation period. J Heart Lung Transplant (2003) 0.79
Prognostic utility of the Seattle Heart Failure Score and amino terminal pro B-type natriuretic peptide in varying stages of systolic heart failure. J Heart Lung Transplant (2013) 0.79
[Diabetic nephropathy--update 2012]. Wien Klin Wochenschr (2012) 0.79
Renal function in heart failure: a disparity between estimating function and predicting mortality risk. Eur J Heart Fail (2013) 0.79
Electrical optimization of cardiac resynchronization in chronic heart failure is associated with improved clinical long-term outcome. Eur J Clin Invest (2010) 0.78
Prevalence of LADA and frequency of GAD antibodies in diabetic patients with end-stage renal disease and dialysis treatment in Austria. Nephrol Dial Transplant (2005) 0.78
Clinical benefit of prostaglandin E1-treatment of patients with ischemic heart disease: stimulation of therapeutic angiogenesis in vital and infarcted myocardium. Biomed Pharmacother (2003) 0.78
CD4+ CD28(null) cells are an independent predictor of mortality in patients with heart failure. Atherosclerosis (2013) 0.78
Safety of a combined strength and endurance training using neuromuscular electrical stimulation of thigh muscles in patients with heart failure and bipolar sensing cardiac pacemakers. Wien Klin Wochenschr (2003) 0.78
Hypertrophic osteoarthropathy caused by PGE1 in a patient with congestive heart failure during cardiac rehabilitation. Wien Klin Wochenschr (2002) 0.78
Oncostatin-M in myocardial ischemia/reperfusion injury may regulate tissue repair. Croat Med J (2004) 0.78
Effect of high-volume and -intensity endurance training in heart transplant recipients. Med Sci Sports Exerc (2004) 0.78